Skip to Content
Search
Search
ABOUT BIORASI
LEADERSHIP & SCIENTIFIC ADVISORS
WHY BIORASI
PARTNERSHIP
TESTIMONIALS
THERAPEUTIC EXPERIENCE
DERMATOLOGY
ONCOLOGY
NEPHROLOGY
NEUROLOGY
CELL THERAPY
FOCUSED SOLUTIONS
RESCUE & RECOVERY
DATA SCIENCE
QUALITY
FEASIBILITY
SAFETY & PHARMACOVIGILANCE
CLINICAL MONITORING
PODCAST
RESOURCE LIBRARY
CONTACT US
ABOUT BIORASI
LEADERSHIP & SCIENTIFIC ADVISORS
WHY BIORASI
PARTNERSHIP
TESTIMONIALS
THERAPEUTIC EXPERIENCE
DERMATOLOGY
ONCOLOGY
NEPHROLOGY
NEUROLOGY
CELL THERAPY
FOCUSED SOLUTIONS
RESCUE & RECOVERY
DATA SCIENCE
QUALITY
FEASIBILITY
SAFETY & PHARMACOVIGILANCE
CLINICAL MONITORING
PODCAST
RESOURCE LIBRARY
CONTACT US
Resource • White Paper
Optimizing the Amount of Investigational Materials in ANDA Studies – Part Two
July 12th, 2017
|
ANDA
|
White Paper
For Dermal Semisolid Clinical Studies White Paper Series
Download White Paper
Share this Story
Related Resources
White Paper
Rare Disease: 5 Steps to Successful Program Development
White Paper
Precision Medicine: What can we learn from precision oncology clinical trials?
View All